AJ Lanigan: Of Course. The truth is, pharma corporations are building large money with remedies like Keytruda and Opdivo that deal with PD-one and PD-L1. Here’s the super neat aspect: think of checkpoints as traffic indicators. You don’t want an immune method that’s running wild like a freight train above waiting for link from Social Bookmarking (3)